Sequential drug decision problems in long-term medical conditions: a case Study of Primary Hypertension Eunju Kim ba, ma, msc

Appendix 6. Pooled standard deviation of SBP lowering effect

A6.1. The studies included in Wald et al’s systematic review
Table A6.1. Diuretics in three months

	Placebo			Diuretics			Total N	Difference
	N	SBP	SD	N	SBP	SD		Mean	SD
Bateman et al (1979)	15	155.4	13.9	15	139.5	17.0	30	15.9	22.0
Chalmers et al (1976a)	16	127.0	14.3	16	117.0	14.3	32	10.0	20.3
Chalmers et al (1976b)	30	158.6	20.7	20	144.8	16.9	50	13.8	26.7
Chalmers et al (1982)	16	164.0	9.2	16	152.0	9.2	32	12.0	13.0
Chrysant et al (1992)	43	153.0	13.1	41	152.0	12.8	84	1.0	18.3
Durel et al (1992)	5	146.7	23.2	5	131.3	15.0	10	15.4	27.6
Erwteman et al (1984)	50	142.9	16.4	50	137.0	13.6	100	5.9	21.3
Frishman et al (1995)	75	-3.9	6.9	133	-8.5	5.8	208	4.6	9.0
Brown et al (1990)	9	-3.8	11.7	10	-11.3	8.9	19	7.5	14.7
Chalmers et al (1986)	21	119.0	13.7	21	113.0	13.7	42	6.0	19.4
Fernández et al (1994)	17	-2.7	13.6	17	-8.5	12.8	34	5.8	18.7
Weighted sum									15.8

Table A6.2. Beta-blockers in three months

	Placebo			BBs			Total N	Difference
	N	SBP	SD	N	SBP	SD		Mean	SD
Bateman et al (1979)	15	155.4	13.9	15	134.6	13.6	30	20.8	19.4
Chalmers et al (1976a)	16	127.0	14.3	16	116.0	14.3	32	11.0	20.3
Chalmers et al (1976b)	30	158.6	20.7	20	142.4	16.9	50	16.2	26.7
Chalmers et al (1982)	16	164.0	9.2	16	147.0	9.2	32	17.0	13.0
Chrysant et al (1992)	43	153.0	13.1	86	152.5	18.5	129	0.5	22.7
Durel et al (1992)	5	146.7	23.2	5	136.6	28.3	10	10.2	36.6
Erwteman et al (1984)	50	142.9	16.4	50	134.6	15.9	100	8.3	22.8
Frishman et al (1995)	75	-3.9	6.9	151	-10.5	6.1	226	6.6	9.3
Wing et al (1988)	16	171.0	8.0	16	154.0	8.0	32	17.0	11.3
Lyons et al (1994)	12	149.0	9.4	12	146.0	19.7	24	3.0	21.8
Weighted sum									16.7

Table A6.3. Calcium channel blockers in three months

	Placebo			CCBs			Total N	Difference
	N	SBP	SD	N	SBP	SD		Mean	SD
Lyons et al (1994)	12	149.0	9.4	12	140.0	18.0	12	9.0	20.3
Maclean et al (1990)	32	163.0	30.9	32	163.0	30.9	136	0.0	43.8
Chan et al (1997)	27	-1.1	2.2	51	-13.1	2.9	156	12.0	3.6
Messerli et al (1998)	152	0.0	.	157	-8.0	1.9	631	8.0	23.8
Scholze et al (1998)	30	-8.1	12.4	59	-11.5	17.4	424	3.4	21.4
Veratran Study Group (1997)	51	148.5	16.1	56	145.5	20.4	272	3.0	26.0
Weighted sum									22.6

Table A6.4. Angiotensin-converting-enzyme inhibitors in three months

	Placebo			ACEIs			Total N	Difference
	N	SBP	SD	N	SBP	SD		Mean	SD
Brown et al (1990)	9	-3.8	11.7	10	-11	15.2	40	7.2	19.2
Chalmers et al (1986)	21	119.0	13.7	21	108.0	13.7	21	11.0	19.4
Fernández et al (1994)	17	-2.7	13.6	18	-12.9	14.0	67	10.2	19.5
Wing et al (1988)	16	171.0	8.0	16	147.0	8.0	16	24.0	11.3
Chan et al (1997)	27	-1.08	2.2	26	-13.30	4.0	156	12.2	4.6
Messerli et al (1998)	152	0.0	.	159	-9	2.0	631	9.0	25.2
Scholze et al (1998)	30	-8.1	12.4	85	-14.1	21.4	424	6.0	24.8
Veratran Study Group (1997)	51	148.5	16.1	50	138.1	12.3	272	10.4	20.3
Weighted sum									21.8

A6.2. The studies included in Wright et al’s systematic review

Table A6.5. Diuretics in one year

	Placebo			Active			Total N	Difference
	N	Mean	SD	N	SBP	SD		Mean	SD
EWPHBPE (1985)	287	-10	23.0	300	-26	17.0	587	-16.0	28.6
HYVET (2008)	1468	-13.9	18.9	1540	-25.7	16.5	3008	-11.8	25.1
HYVET pilot (2003)	394	-7	11.0	386	-29.5	13.0	780	-22.5	17.0
Kuramoto et al (1981)	32	1.0	17.9	32	-9	16.1	64	-10.0	24.1
MRC-O (1992)	2213	167.0	17.9	1081	151.0	16.1	3294	-16.0	24.1
PATS (1995)	2824	149.6	19.2	2841	144.5	18.0	5665	-5.1	26.3
SHEP (1991)	2371	-13.6	17.3	2365	-28	15.7	4736	-14.4	23.4
SHEP-P (1989)	108	-16	17.9	443	-32	16.1	551	-16.0	24.1
HSCSG (1974)	171	0.0	17.9	179	-27	16.1	350	-27.0	24.1
MRC-TMH (1985)	8654	-13	17.9	4297	-25.2	16.1	12951	-12.2	24.1
OSLO (1986)	379	147.0	17.9	406	130.0	16.1	785	-17.0	24.1
USPHSHCSG (1977)	178	1.5	16.7	175	-16.5	19.4	353	-18.0	25.6
VA-II (1970)	194	4.2	17.9	186	-27.2	16.1	380	-31.4	24.1
Wolff et al (1966)	42	15.0	17.9	45	-21.2	16.1	87	-36.2	24.1
Weighted sum									24.4

Table A6.6. Beta-blocker in one year

	Placebo			Active			Total N	Difference
	N	Mean	SD	N	Mean	SD		Mean	SD
Dutch TIA (1993)	741	-2.2	16.0	732	-8	16.0	1473	-5.8	22.6
MRC-O (1992)	2213	167.0	17.9	1102	156.0	16.1	3315	-11.0	24.1
MRC-TMH (1985)	8654	-13	17.9	4403	-23	16.1	13057	-10.0	24.1
TEST (1995)	348	0.0	16.0	372	-4	16.0	720	-4.0	22.6
UKPDS39 (1998)	156	-6	16.0	112	-16	14.0	268	-10.0	21.3
Weighted sum									23.8

Table A6.7. Calcium channel blockers in one year

	Placebo			Active			Total N	Difference
	N	Mean	SD	N	Mean	SD		Mean	SD
SYST-EUR (1997)	2297	-11.9	16.0	2398	-20.8	17.0	4695	-8.9	23.3

Table A6.8. Angiotensin-converting-enzyme inhibitors in three months

	Placebo			Active			Total N	Difference
	N	Mean	SD	N	Mean	SD		Mean	SD
HYVET (2008)	394	-7	11.0	397	-30.9	13.0	791	-23.9	17.0
UKPDS39 (1998)	156	-6	16.0	124	-15	14.0	280	-9.0	21.3
Weighted sum									18.0

A6.3. References

Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, et al. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial (EWPHBPE). lancet 1985;I:1349–1354.

Bateman DN, Dean CR, Mucklow JC, et al. Atenolol and chlorthalidone in combination for hypertension. Br J Clin Pharmacol. 1979;7:357-363.

Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ: HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358(18):1887–1898.

Brown CL, Backhouse CI, Grippat JC, Santoni JP. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol. 1990;39:327-332.

Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, Nunes M, Peters R, Staessen JA, Thijs L. Results of the pilot study for the Hypertension in the Very Elderly Trial (HYVET pilot). J Hypertens 2003;21:2409–2417.

Chalmers JP, Korner PI, Tiller DJ, et al. Double-blind factorial trial of prindolol and hydrochlorothiazide in hypertension. Med J Aust. 1976a;1:650-653.

Chalmers J, Horvath J, Tiller D, Bune A. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Lancet. 1976b;2:328-331.

Chalmers JP, Wing LMH, Grygiel JJ, et al. Effects of once daily indapamide and pindolol on blood pressure, plasma aldosterone concentration and plasma renin activity in a general practice setting. Eur J Clin Pharmacol. 1982;22:191-196.

Chalmers JP, Morris MJ, Wing LMH, et al. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study. Aust NZ J Med. 1986;16:475-480.

Chan P, Lin C, Tomlinson B, et al. Additive effects of diltiazem and lisinopril in treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens. 1997;10:743-749

Chrysant SG, Chappel C, Farnham J, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol. 1992;32:61-65.

Durel LA, Hayashi PJ, Weidler DJ, Schneiderman N. Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination. J Clin Pharmacol. 1992;32:564-570.

Dutch TIA trial study group. Trial of secondary prevention with atenolol after transient ischemic attack or non-disabling ischemic stroke. Stroke 1993;24:543–548.

Eriksson S, Olofsson BO, Wesley PO, for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21–25.

Erwteman TM, Nagelkerke N, Lubsen J, et al. b Blockade, diuretics, and salt restriction for the management of mild hypertension: a randomised double blind trial. BMJ. 1984;289:406-409.

Frishman WH, Burris JF, Mroczek WJ, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol. 1995;35:182-188.

Fernández M, Madero R, González D, et al. Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients. Hypertension. 1994;23(Suppl I):I-207-210.

Hypertension-Stroke Cooperative Study Group (HSCSG). Effect of antihypertensive treatment on stroke recurrence. JAMA 1974;229:409–418.

Kuramoto K, et al.Prospective study on the treatment of mild hypertension in the aged. Jpn heart J 1981;22:75–85.

Leren P, et al. Oslo hypertension study. Drugs 1986;31(Suppl 1): 41–45.

Lyons D, Fowler G, Webster J, et al. An assessment of lacidipine and atenolol in mild to moderate hypertension. Br J Clin Pharmacol. 1994;37:45-51.

Maclean D, Mitchell ET, Lewis R, et al. Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension. Br J Clin Pharmacol. 1990;29:455-463.

Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens. 1998;11:322-327.

Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291(6488):97–104.

MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405–412.

PATS collaborating group. Post-stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal 1995;108(9):710–7.

Perry HM, et al.Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke 1989;20:4–13.

Scholze J, Zilles P, Compagnone D. Verapamil SR and trandolapril combination therapy in hypertension—a clinical trial of factorial design. Br J Clin Pharmacol. 1998;45:491-495.

SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA 1991;265:3255–3264.

Staessen JA. Fagard R. Thijs L. Celis H. Arabidze GG, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension (SYST-EUR). Lancet 1997;350:757–764.

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J 1998;317:713–720.

US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a tenyear intervention trial. Circ Res 1977;40(Suppl 1):98–105.

Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II (VA-II). Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143–1152.

Veratran Study Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure. Am J Hypertens. 1997;10:492-499.

Wing LMH, Chalmers JP, West MJ, et al. Enalapril and atenolol in essential hypertension: attenuation of hypertensive effects in combination. Clin Exp Hypertens. 1988;10:119-133.

Wolff FW, Lindeman RD. Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227–240.